Idogen’s first trading day on Nasdaq First North noted at Times Square in New York
Idogen AB (“Idogen”) announced that as of today, the company’s share is being traded on Nasdaq First North Growth Market. The traditional ringing of the bell was skipped owing to the prevailing COVID-19 pandemic, but the event was noted on the Nasdaq trading floor at Times Square in New York. Idogen is developing completely new types of cell therapies that have the potential to improve the treatment of hemophilia A and reduce the risk of transplanted kidneys being rejected. The listing on Nasdaq First North Growth Market is a natural step in Idogen’s development. Over the past year, the